Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 2 chart positions in 2 markets.
By chart position
- 🇷🇴RO · Science#175500 to 3K
- 🇹🇷TR · Science#197500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
500 to 3K🎙 Weekly cadence·48 episodes·Last published yesterday - Monthly Reach
Unique listeners across all episodes (30 days)
1K to 6K🇷🇴50%🇹🇷50% - Active Followers
Loyal subscribers who consistently listen
400 to 2.4K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 11 epsHosts
Recent guests
Recent episodes
For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress
Jul 8, 2026
Unknown duration
Targeted Therapies for Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit
Jun 30, 2026
Unknown duration
EGFR-Mutated Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit
Jun 27, 2026
Unknown duration
First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer — An Interview with Prof Martin Reck
Jun 18, 2026
Unknown duration
Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Jun 9, 2026
58m 47s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/8/26 | For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress | Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics:Introduction (0:00)Overview of Antibody-Drug Conjugates (ADCs) (2:07)Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23)Currently Available ADCs for Gynecologic Cancer Management (26:37)Currently Available ADCs for Lung Cancer Management (44:07)Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55)Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07)Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01)NCPD information and select publications | — | ||||||
| 6/30/26 | Targeted Therapies for Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit | Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics: Introduction (0:00)Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09)Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56)CME information and select publications | — | ||||||
| 6/27/26 | EGFR-Mutated Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit | Featuring perspectives from Dr Jonathan Goldman and Dr Zofia Piotrowska, including the following topics:Introduction (0:00)Current Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Dr Goldman (0:38)Nonmetastatic EGFR-Mutated NSCLC, Exon 20 Insertion Mutations and Novel Agents — Dr Piotrowska (33:20)CME information and select publications | — | ||||||
| 6/18/26 | First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer — An Interview with Prof Martin Reck | Featuring an interview with Prof Martin Reck, including the following topics:Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00)Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25)Considerations with maintenance therapy for ES-SCLC (9:31)Considerations with immunotherapy for ES-SCLC (13:12)Curability of SCLC with systemic therapy (15:17)Data with chemoimmunotherapy for patients with poor performance status (25:55)Future developments in therapy for SCLC (30:11)Rapid fire: Small Cell 101 (35:45)CME information and select publications | — | ||||||
| 6/9/26 | Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances✨ | small cell lung cancerclinical trials+3 | Dr Christine L HannDr Jacob Sands | Johns Hopkins University School of MedicineDana-Farber Cancer Institute | Baltimore, MarylandBoston, Massachusetts | small cell lung cancerclinical trials+3 | — | 58m 47s | |
| 4/27/26 | EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances✨ | EGFR mutationnon-small cell lung cancer+3 | Dr Suresh S RamalingamDr Helena Yu | EGFRnon-small cell lung cancer | — | EGFR mutationnon-small cell lung cancer+3 | — | 57m 26s | |
| 4/17/26 | Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays✨ | lung cancercirculating tumor DNA+3 | Dr Natalie Vokes | The University of Texas MD Anderson Cancer CenterLung Cancer Update | — | lung cancercirculating tumor DNA+3 | — | 27m 12s | |
| 2/27/26 | Extensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance Therapy✨ | lung cancersmall cell lung cancer+3 | Dr Hossein BorghaeiDr Anne Chiang | Fox Chase Cancer CenterYale Cancer Center | Philadelphia, PennsylvaniaNew Haven, Connecticut | extensive-stage small cell lung cancerfirst-line management+3 | — | 59m 42s | |
| 12/17/25 | Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy✨ | small cell lung cancerfirst-line therapy+3 | Dr Luis Paz-AresDr Shields | Spanish National Oncology Research CenterIndiana University School of Medicine | — | extensive-stagesmall cell lung cancer+4 | — | 57m 46s | |
| 12/12/25 | Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network✨ | lung cancertreatment landscape+3 | Dr Justin F GainorDr Corey J Langer+1 | American Oncology Network | — | lung cancertreatment+3 | — | 1h 43m 11s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 12/10/25 | HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach✨ | HER2-altered non-small cell lung cancertreatment strategies+3 | Dr John Heymach | The University of Texas MD Anderson Cancer CenterLung Cancer Update | — | HER2non-small cell lung cancer+3 | — | 1h 05m 13s | |
| 11/10/25 | Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates✨ | lung cancerantibody-drug conjugates+3 | Dr Aaron Lisberg | TROP2-directed antibody-drug conjugatesUniversity of California, Los Angeles | non-small cell lung cancer | lung cancerTROP2+3 | — | 21m 21s | |
| 10/20/25 | Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates✨ | lung cancerTROP2+3 | Dr Aaron Lisberg | TROP2-directed antibody-drug conjugatesUniversity of California, Los Angeles | non-small cell lung cancer | lung cancerTROP2+3 | — | 24m 47s | |
| 9/14/25 | Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates✨ | lung cancerTROP2-directed antibody-drug conjugates+3 | Dr Jacob Sands | Dana-Farber Cancer Institute | Boston, Massachusetts | lung cancerTROP2+4 | — | 23m 19s | |
| 8/22/25 | Small Cell Lung Cancer — Expert Perspectives on Actual Patient Cases✨ | small cell lung cancertherapies+3 | Dr Stephen V LiuDr Charles Rudin | Georgetown University HospitalMemorial Sloan Kettering Cancer Center | Washington, DCNew York | small cell lung cancertherapies+3 | — | 58m 18s | |
| 8/18/25 | Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates | Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here. | — | ||||||
| 8/8/25 | Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances | Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation. CME information and select publications here. | — | ||||||
| 7/17/25 | Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates | Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations. CME information and select publications here. | — | ||||||
| 7/8/25 | For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS Congress | Dr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the management of small cell lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here. | — | ||||||
| 6/20/25 | EGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting | Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual meeting. CME information and select publications here. | — | ||||||
| 6/10/25 | Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances | Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer. CME information and select publications here. | — | ||||||
| 5/18/25 | Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit | Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches. CME information and select publications here. | — | ||||||
| 4/30/25 | EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit | Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer. CME information and select publications here. | — | ||||||
| 4/26/25 | For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress | Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here. | — | ||||||
| 4/10/25 | First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor | Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. CME information and select publications here. | — | ||||||
Showing 25 of 54
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
2 placements across 2 markets.
Chart Positions
2 placements across 2 markets.